Orphan Drug Development: Opportunities and Challenges from a Midsized to Large Company Perspective

被引：0

作者：

Rosann Reinhart

Krysten Madrzjewski

机构：

[1] EMD Serono,

[2] Inc.,undefined

来源：

Drug information journal : DIJ / Drug Information Association | 2010年 / 44卷

关键词：

Orphan drug; Rare disease; Orphan legislation; Orphan designation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Orphan diseases may be one of the last frontiers in drug development. With an estimated 50 million or more people affected across Europe and North America by over 6,000 rare diseases, the unmet medical need is daunting. This research explores the question of whether the opportunities outweigh the challenges and provide incentives for midsized to large pharmaceutical and biotechnology companies to invest in this area.

引用

页码：101 / 109

页数：8

共 6 条

[1] Orphan Drug Development: Opportunities and Challenges from a Midsized to Large Company Perspective
Reinhart, Rosonn
Modrzjewski, Krysten
DRUG INFORMATION JOURNAL, 2010, 44 (02): : 101 - 109
[2] Challenges in orphan drug development and regulatory policy in China
Cheng, Alice
Xie, Zhi
ORPHANET JOURNAL OF RARE DISEASES, 2017, 12 : 1 - 8
[3] Challenges in orphan drug development and regulatory policy in China
Alice Cheng
Zhi Xie
Orphanet Journal of Rare Diseases, 12
[4] Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy
Bhattacharjee, Sonali
Nandi, Saikat
CANCERS, 2018, 10 (09)
[5] Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications
Zhao, Zhiyao
Pei, Zhongyang
Hu, Anxia
Zhang, Yuhui
Chen, Jing
ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
[6] Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications
Zhiyao Zhao
Zhongyang Pei
Anxia Hu
Yuhui Zhang
Jing Chen
Orphanet Journal of Rare Diseases, 18

← 1 →